Johnson & Johnson released data from the Phase III ICONIC-LEAD trial subgroup analysis on icotrokinra for plaque psoriasis treatment. Adolescents showed better skin improvement with the drug, demonstrating safety. The oral peptide targets IL-23 receptor, evaluated in ages 12+.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing